New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCortagen vs Dulaglutide

Cortagen vs Dulaglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityRecovery & Repair
Cortagen
GLP-1 / Weight Loss Agonists
Dulaglutide
Summary
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
Half-Life
Short peptide half-life; gene regulatory effects persist beyond peptide clearance
~5 days
Admin Route
SubQ, IM, Oral
SubQ
Research
Typical Dose
10 mg SC or IM daily
0.75 mg → 1.5 mg
Frequency
Once daily
Once weekly
Key Benefits
  • Cardioprotective — protects cardiac tissue from ischemic damage
  • Promotes cardiac regeneration and repair
  • Improves vascular endothelium function
  • Reduces atherosclerosis progression
  • Anti-aging effect on heart muscle cells
  • Improves cardiac output and exercise capacity
  • Reduces oxidative stress in cardiovascular tissue
  • May reduce arrhythmia frequency
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
Side Effects
  • Excellent safety profile
  • Mild injection site reactions
  • Rare: transient hypotension
  • Rare: mild arrhythmia at initiation in cardiac patients
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
Stacks With